Cancer genetics and cytogenetics ppt powerpoint presentation icon shapes

You'll see p53 mutations everywhere - like half of all cancers have them since it's basically the cell's emergency brake. KRAS shows up a ton in colon and lung stuff. BRCA1/BRCA2 are the famous breast/ovarian ones everyone knows about. PIK3CA hits breast cancer pretty often too. Oh, and there's tissue-specific ones like APC for colorectal, EGFR mutations in lung adenocarcinoma. Honestly the sequencing is getting so cheap now that we're finding new ones constantly. But here's the thing - knowing your patient's exact mutations matters way more than it used to because targeted therapies actually work when you can match them up right.

Yeah so basically having one of those hereditary cancer things means you start screening way earlier - like 10-20 years before everyone else. BRCA carriers get annual breast MRIs starting at 25-30 instead of waiting until 40 for regular mammograms. Lynch syndrome has its own crazy schedule too. Some people even go the prophylactic surgery route, which honestly seems terrifying but I get it. The screening gets way more intense overall - different imaging, more frequent checkups. You'll definitely want genetic counseling first though because they map out what makes sense for your specific situation. Cookie-cutter stuff doesn't really work here.

So basically, next-gen sequencing lets you dig way deeper into cancer genetics than the old methods. The data you get is insane - whole tumor genomes analyzed fast and cheap. Mutations, copy number changes, structural rearrangements that drive cancer growth - you'll catch stuff that would've been missed before. Plus you can watch how tumors change over time, which is wild when you think about it. The cool part? It's actually useful for treatment now. Sequence someone's tumor and you can pick therapies based on what you find. Total game-changer for personalized medicine.

Hey! So epigenetic changes are massive in cancer development - they mess with gene expression without touching the actual DNA sequence. Think DNA methylation and histone modifications flipping genes on/off when they shouldn't be. What's wild is these changes are reversible, unlike mutations. That's why there's tons of epigenetic drugs in trials right now targeting things like DNA methyltransferases. Honestly, I think this area's gonna explode in the next few years. If you're doing cancer research, you should definitely look at epigenetics alongside the usual genetic stuff.

So basically, they test your tumor to see what mutations are driving it, then match you with drugs that actually target those specific pathways. EGFR mutation in lung cancer? Erlotinib or osimertinib will crush it way better than regular chemo. They'll check stuff like HER2 status, BRCA mutations, PD-L1 expression - honestly the whole process is pretty incredible now. Each mutation opens different treatment doors. The trick is getting that comprehensive testing done right away instead of just guessing what might work. Makes such a huge difference in outcomes.

Look, the big stuff you'll deal with is consent, privacy, and family drama. Patients need to really get what they're signing up for - like insurance issues and how heavy the results can be psychologically. But here's where it gets messy: if someone tests positive, their relatives are basically affected too even though they never agreed to it. Creates all this weird family tension. Oh, and there's the whole debate about testing kids for cancers they won't get until they're adults. Honestly? Get a genetic counselor involved from the start. Makes everything smoother.

So polygenic risk scores take hundreds of tiny genetic variants and combine them to show cancer risk way better than just looking at one big mutation. They're filling in that "missing heritability" gap we couldn't figure out before. Really helpful for breast and prostate cancers where family history doesn't always add up, you know? Doctors can use the scores to decide when to start screening or how often to do it. Though honestly, they work best when you combine them with other risk factors - age, lifestyle, all that stuff. Pretty wild how much more personalized medicine is getting.

So apparently your gut bacteria can mess with cancer genes - like actually change how oncogenes and tumor suppressors work. Wild, right? They even screw with DNA repair stuff. What's crazy is some bacteria make immunotherapy treatments way more effective, others tank them completely. Depends what's hanging out in your intestines. Colorectal cancer risk, checkpoint inhibitor response - your microbiome affects all of it. Honestly if you're doing any cancer genetics work, you gotta throw in microbiome analysis now. Can't get the full story without it.

Start with a solid three-generation pedigree - that's your baseline. Get cancer types, diagnosis ages, even benign stuff that might matter. Here's what people miss: healthy relatives are just as important as the sick ones. You need the whole picture, right? Walk through it together with your patient so they actually get how their family history connects to their own risk. That collaboration piece is huge. Use what you find to figure out testing and screening recommendations. Honestly, patients understand their situation way better when you map it out visually like this.

So genetic heterogeneity is basically why cancer treatments are such a pain. You'll target one group of cells successfully, but then other cells in the same tumor have totally different mutations and just keep growing. Think whack-a-mole but way more frustrating. That's why patients often respond well initially, then develop resistance later - the sneaky resistant cells take over once you've killed off their competition. Honestly, this is pushing more docs toward combination therapies instead of single drugs. If you can, try getting tissue samples from multiple tumor sites since they're all probably different.

Dude, the pattern recognition stuff is insane - AI can spot correlations across thousands of genes that we'd never catch manually. You can predict cancer risk from variants, find new drug targets, personalize treatments based on someone's specific profile. Drug discovery is way faster now too since they model how compounds interact with mutations. Honestly the algorithms are getting a little too good at this, it's wild. If you're dealing with big genomic datasets, check out DeepVariant or maybe team up with some bioinformatics people. Worth exploring for sure.

Honestly, cancer genetics are a total mess - even in one tumor you've got cells with completely different mutations. Getting the therapy to actually reach cancer cells without hitting healthy ones? Still super hard. Tumors are basically little escape artists too, they figure out ways around whatever you throw at them. Oh, and your immune system might just attack the delivery method before it even gets there. Kind of defeats the purpose, right? I'd say look into combination treatments instead. No single approach is gonna solve this thing.

So basically, your genetic background really affects cancer risk and treatment responses. BRCA mutations show up way more in Ashkenazi Jewish families, while certain lung cancers hit East Asians more often. Treatment-wise, some people just process chemo differently because their liver enzymes work differently - it's all genetic. Honestly, the whole personalized medicine thing is pretty cool when you think about it. We're finally getting better at matching treatments to people's actual genetics instead of just throwing standard protocols at everyone. When you're looking at cases, ancestry should definitely be on your radar alongside the usual risk factors.

So tumor suppressor genes are like your cells' brakes - they stop crazy growth from happening. When they get messed up or deleted, you lose that "stop" signal and that's how a lot of cancers start. p53 and RB are the big ones everyone knows, plus BRCA1/2 obviously. It's the opposite of oncogenes though - these cause problems when they're switched OFF instead of on. That's why you see all that loss of heterozygosity stuff in tumors. Honestly, if you're looking at patient samples, I'd check for deletions in these pathways first. Way more straightforward than some other approaches.

Honestly, most people just don't know what genetic research actually involves - that's the biggest barrier. Clear campaigns explaining how studies work and what privacy protections exist make a huge difference. People get way less freaked out when they understand their data won't be used against them or sold off somewhere. Working with local doctors and community groups is clutch since people already trust them. Oh, and emphasizing how diverse participation helps everyone get better treatments really resonates. It's wild how much fear disappears once you break down the science into normal language.